# EDGAR Filing Document

**Accession Number:** 0001119643
**File Stem:** 0001493152-25-028946
**Filing Date:** 2025-12
**Character Count:** 160862
**Document Hash:** 3c14774401b8d4081fc46edf235ea2d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-028946.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001493152-25-028946

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 77

**CONFORMED PERIOD OF REPORT**: 20240630

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NUTRA PHARMA CORP
- **CENTRAL INDEX KEY:** 0001119643
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 912021600
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-32141
- **FILM NUMBER:** 251597750

**BUSINESS ADDRESS:**
- **STREET 1:** 12538 W. ATLANTIC BLVD.
- **CITY:** CORAL SPRINGS
- **STATE:** FL
- **ZIP:** 33071
- **BUSINESS PHONE:** (954) 509-0911

**MAIL ADDRESS:**
- **STREET 1:** 12538 W. ATLANTIC BLVD.
- **CITY:** CORAL SPRINGS
- **STATE:** FL
- **ZIP:** 33071

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYBER VITAMIN COM
- **DATE OF NAME CHANGE:** 20000717

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

(Mark One)

☒ QUARTERLY
 REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, 2024

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from _________ to ________

Commission file numbers 000-32141

**NUTRA PHARMA CORP.**

(Name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **California** | **91-2021600** |
| (State or Other<br> Jurisdiction of Organization) | (IRS Employer<br> Identification Number) |

---

---

| | |
|:---|:---|
| **6400 Park of Commerce Blvd, Suite 1B**<br> **Boca Raton, FL** | **33487** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(954) 509–0911</u>**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Ticker symbol(s)** | **Name of each exchange on which registered** |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S–T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non–accelerated filer, a smaller reporting company, or an emerging growth company.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☐ Smaller reporting company ☒ <br> Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes ☐ No ☒

As of December 23, 2025, there were 7,099,727,214 shares of common stock and 12,000,000 shares of Series B preferred stock issued and outstanding.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **[PART I. FINANCIAL INFORMATION](#a_001)** | F-1 |
| [Item 1. Financial Statements](#a_002) | F-1 |
| [Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023](#a_003) | F-1 |
| [Condensed Consolidated Statements of Operations for the Three and Six months ended June 30, 2024 and 2023 (Unaudited)](#a_004) | F-2 |
| [Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Three months ended June 30, 2024 and 2023 (Unaudited)](#a_005) | F-3 |
| [Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Six months ended June 30, 2024 and 2023 (Unaudited)](#a_006) | F-4 |
| [Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2024 and 2023 (Unaudited)](#a_007) | F-5 |
| [Notes to Condensed Consolidated Financial Statements (Unaudited)](#a_008) | F-6 |
| [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_009) | 4 |
| [Item 3. Quantitative and Qualitative Disclosures about Market Risk](#a_010) | 10 |
| [Item 4. Controls and Procedures](#a_011) | 10 |
| **[PART II. OTHER INFORMATION](#a_012)** | 11 |
| [Item 1. Legal Proceedings](#a_013) | 11 |
| [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#a_014) | 12 |
| [Item 3. Defaults Upon Senior Securities](#a_015) | 12 |
| [Item 4. Mine Safety Disclosure](#a_016) | 12 |
| [Item 5. Other Information](#a_017) | 12 |
| [Item 6. Exhibits](#a_018) | 12 |

---

**Nutra Pharma Corp ("Nutra Pharma") and its wholly owned subsidiary, ReceptoPharm, Inc. ("ReceptoPharm"), are referred to herein as "we", "our" or "us" (ReceptoPharm is also individually referred to herein).**

**Forward Looking Statements**

This Quarterly Report on Form 10–Q for the period ending June 30, 2024, contains forward–looking statements that involve risks and uncertainties, as well as assumptions that if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward–looking statements. The words or phrases "would be," "will allow, "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward–looking statements." We are subject to risks detailed in Item 1(a). All statements other than statements of historical fact are statements that could be deemed forward–looking statements, including: (a) any projections of revenue, gross margin, expenses, earnings or losses from operations, synergies or other financial items; and (b) any statements of the plans, strategies and objectives of management for future operations; and (c) any statement concerning developments, plans, or performance. Unless otherwise required by applicable law, we do not undertake and we specifically disclaim any obligation to update any forward–looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**NUTRA PHARMA CORP.**

**Condensed Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2024** | **December 31,**<br>**2023** |
|  | **(Unaudited)** | |
| <u>ASSETS</u> |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $- | $- |
| &nbsp;&nbsp;&nbsp;Accounts receivable | 22593 | 22433 |
| &nbsp;&nbsp;&nbsp;Inventory, current portion | 23760 | 19544 |
| &nbsp;&nbsp;&nbsp;Other receivable | 5000 | 5000 |
| &nbsp;&nbsp;&nbsp;Convertible notes receivable, net of discount | 44050 | 6600 |
| &nbsp;&nbsp;&nbsp;Receivable from sale of Stemsation stocks | 52800 | 35200 |
| &nbsp;&nbsp;&nbsp;Investment in Stemsation stocks | 17600 | 35200 |
| &nbsp;&nbsp;&nbsp;Settlement receivables | 160084 | 160084 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 33999 | 29999 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 359886 | 314060 |
| Inventory, less current portion | 114670 | 125170 |
| Property and equipment, net | 14122 | 17842 |
| Operating lease right-of-use assets, net | 133487 | 174522 |
| Security deposit | 8803 | 8803 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $630968 | $640397 |
| <u>LIABILITIES AND STOCKHOLDERS' DEFICIT</u> |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $870413 | $762955 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 2005825 | 1900497 |
| &nbsp;&nbsp;&nbsp;Accrued payroll due to officers | 1504790 | 1373693 |
| &nbsp;&nbsp;&nbsp;Deferred revenue - related party | 227762 | 233331 |
| &nbsp;&nbsp;&nbsp;Accrued interest to related parties | 178971 | 168724 |
| &nbsp;&nbsp;&nbsp;Due to officers | 1108375 | 659433 |
| &nbsp;&nbsp;&nbsp;Derivative liabilities | 697965 | 661257 |
| &nbsp;&nbsp;&nbsp;Other debt, net of discount, current portion | 8309751 | 8321801 |
| &nbsp;&nbsp;&nbsp;SBA notes payable, current portion | 7950 | 6243 |
| &nbsp;&nbsp;&nbsp;Operating lease obligations, current portion | 88461 | 83703 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 15000263 | 14171637 |
| SBA notes payable, less current portion | 141950 | 143657 |
| Operating lease obligations, less current portion | 47636 | 93411 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 15189849 | 14408705 |
| Commitments and Contingencies (Note 12) |  |  |
| Stockholders' deficit: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value, 20,000,000 shares authorized and 12,000,000 Series B Preferred shares authorized, issued and outstanding | 12000 | 12000 |
| &nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, 12,000,000,000 shares authorized; 7,099,727,214 and 7,039,727,214 shares issued and outstanding | 7099727 | 7064727 |
| &nbsp;&nbsp;&nbsp;Common stock to be issued | 469678 | 469678 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 53599261 | 53630761 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (75739547) | (74945474) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' deficit | (14558881) | (13768308) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' deficit | $630968 | $640397 |

---

See the accompanying notes to the unaudited condensed consolidated financial statements

**NUTRA PHARMA CORP.**

**Condensed Consolidated Statements of Operations**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended<br> June 30,** | **For the Three Months Ended<br> June 30,** | **For the Six Months Ended<br> June 30,** | **For the Six Months Ended<br> June 30,** |
|  | **2024** | **2023** | **2024** | **2023** |
| Net sales | $51710 | $52398 | $89442 | $106920 |
| Net sales to a related party | 36759 | 112489 | 71708 | 212991 |
| Cost of sales | (18624) | (80252) | (41108) | (132177) |
| Reserve for supplier advances for purchases | (15000) | - | (30000) | - |
| Gross profit | 54845 | 84635 | 90042 | 187734 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 274338 | 266939 | 604844 | 663259 |
| &nbsp;&nbsp;&nbsp;Bad debt expense - related party | - | - | - | 105465 |
| Total operating expenses | 274338 | 266939 | 604844 | 768724 |
| Loss from operations | (219493) | (182304) | (514802) | (580990) |
| Other income (expenses) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Other income | 3150 | 31894 | 3450 | 32794 |
| &nbsp;&nbsp;&nbsp;Interest expense | (81847) | (85904) | (163404) | (224021) |
| &nbsp;&nbsp;&nbsp;Interest expense to related parties | (5199) | (4618) | (10247) | (9054) |
| &nbsp;&nbsp;&nbsp;Change in fair value of convertible notes and derivatives | (56250) | (38314) | (122990) | (90185) |
| &nbsp;&nbsp;&nbsp;Stock based loan modification cost |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net gain (loss) on settlement of debt and accrued expenses | (7500) | - | 13920 | (350) |
| Total other expenses | (147646) | (96942) | (279271) | (290816) |
| Loss before income taxes | (367139) | (279246) | (794073) | (871806) |
| Provision for income taxes | - | - | - | - |
| Net loss | $(367139) | $(279246) | $(794073) | $(871806) |
| Net loss per share - basic and diluted | $(0.00) | $(0.00) | $(0.00) | $(0.00) |
| Weighted average number of shares outstanding during |  |  |  |  |
| &nbsp;&nbsp;&nbsp;the period - basic | 7657102214 | 7597102214 | 7650179137 | 7597102214 |
| Weighted average number of shares outstanding during |  |  |  |  |
| &nbsp;&nbsp;&nbsp;the period - diluted | 7657102214 | 7597102214 | 7650179137 | 7597102214 |

---

See the accompanying notes to the unaudited condensed consolidated financial statements

**NUTRA PHARMA CORP.**

**Condensed Consolidated Statements of Changes in Stockholders' Deficit**

**For the Three Months Ended June 30, 2024 and 2023**

**(Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | | | | | | | |
|  | **Series B** | **Series B** | **Common Stock** | **Common Stock** | **C.S to be issued** | **C.S to be issued** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance - March 31, 2024** | **12000000** | $**12000** | **7064727214** | $**7064727** | **592375000** | $**473178** | $**53630761** | $**(75372408)** | $**(14191742)** |
| &nbsp;&nbsp;&nbsp;Common stock issued for debt modification and penalty- recognized in Q1, issued in Q2 |  |  | 35000000 | 35000 | (35000000) | (3500) | (31500) |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | - | (367139) | (367139) |
| **Balance - June 30, 2024** | **12000000** | $**12000** | **7099727214** | $**7099727** | **557375000** | $**469678** | $**53599261** | $**(75739547)** | $**(14558881)** |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | | | | | | | |
|  | **Series B** | **Series B** | **Common Stock** | **Common Stock** | **C.S to be issued** | **C.S to be issued** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance - March 31, 2023** | **12000000** | $**12000** | **7039727214** | $**7039727** | **557375000** | $**469678** | $**53653261** | $**(74144678)** | $**(12970012)** |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | - | (279246) | (279246) |
| **Balance - June 30, 2023** | **12000000** | $**12000** | **7039727214** | $**7039727** | **557375000** | $**469678** | $**53653261** | $**(74423924)** | $**(13249258)** |

---

See the accompanying notes to the unaudited condensed consolidated financial statements

**NUTRA PHARMA CORP.**

**Condensed Consolidated Statements of Changes in Stockholders' Deficit**

**For the Six Months Ended June 30, 2024 and 2023**

**(Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | | | | | | | |
|  | **Series B** | **Series B** | **Common Stock** | **Common Stock** | **C.S to be issued** | **C.S to be issued** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance - December 31, 2023** | **12000000** | $**12000** | **7064727214** | $**7064727** | **557375000** | $**469678** | $**53630761** | $**(74945474)** | $**(13768308)** |
| &nbsp;&nbsp;&nbsp;Common stock issued for debt modification and penalty |  |  |  |  | 35000000 | 3500 |  |  | 3500 |
| &nbsp;&nbsp;&nbsp;Common stock issued for debt modification and penalty- recognized in Q1, issued in Q2 |  |  | 35000000 | 35000 | (35000000) | (3500) | (31500) |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | - | (794073) | (794073) |
| **Balance - June 30, 2024** | **12000000** | $**12000** | **7099727214** | $**7099727** | **557375000** | $**469678** | $**53599261** | $**(75739547)** | $**(14558881)** |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | | | | | | | |
|  | **Series B** | **Series B** | **Common Stock** | **Common Stock** | **C.S to be issued** | **C.S to be issued** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance - December 31, 2022** | **12000000** | $**12000** | **7039727214** | $**7039727** | **557375000** | $**469678** | $**53653261** | $**(73552118)** | $**(12377452)** |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | - | (871806) | (871806) |
| **Balance - June 30, 2023** | **12000000** | $**12000** | **7039727214** | $**7039727** | **557375000** | $**469678** | $**53653261** | $**(74423924)** | $**(13249258)** |

---

See the accompanying notes to the unaudited condensed consolidated financial statements

**NUTRA PHARMA CORP.**

**Condensed Consolidated Statements of Cash Flows**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended June 30,** | **For the Six Months Ended June 30,** |
|  | **2024** | **2023** |
| Cash flows from operating activities: |  |  |
| Net loss | $(794073) | $(871806) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Change in reserve for supplier advances for purchases | 30000 |  |
| &nbsp;&nbsp;&nbsp;Bad debt expense - related party |  | 105465 |
| &nbsp;&nbsp;&nbsp;(Gain) loss on settlement of debt and accrued expense | (13920) | 350 |
| &nbsp;&nbsp;&nbsp;Depreciation | 3720 | 10886 |
| &nbsp;&nbsp;&nbsp;Amortization of convertible notes receivable discount | (3450) | (2431) |
| &nbsp;&nbsp;&nbsp;Change in fair value of convertible notes and derivatives | 122990 | 90185 |
| &nbsp;&nbsp;&nbsp;Amortization of loan discount | 75560 | 93532 |
| &nbsp;&nbsp;&nbsp;Amortization of operating lease right-of-use assets | 41035 | 37969 |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Increase in accounts receivable | (160) | (90) |
| &nbsp;&nbsp;&nbsp;Decrease (increase) in inventory | 6284 | (6079) |
| &nbsp;&nbsp;&nbsp;Increase in other receivable | (33000) | (36363) |
| &nbsp;&nbsp;&nbsp;Decrease (increase) in prepaid expenses and other current assets | (34000) | 2652 |
| &nbsp;&nbsp;&nbsp;Increase in accounts payable | 107458 | 16095 |
| &nbsp;&nbsp;&nbsp;Increase in accrued expenses | 129936 | 94754 |
| &nbsp;&nbsp;&nbsp;Increase in accrued payroll due to officers | 131097 | 80000 |
| &nbsp;&nbsp;&nbsp;(Decrease) increase in deferred revenue - related party | (5569) | 130658 |
| &nbsp;&nbsp;&nbsp;Increase in accrued interest to related parties | 12287 | 11280 |
| &nbsp;&nbsp;&nbsp;Decrease in operating lease obligations | (41017) | (36673) |
| Net cash used in operating activities | (264822) | (279616) |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Convertible notes receivable advances | (1000) | (12310) |
| &nbsp;&nbsp;&nbsp;Convertible notes receivable repayments | - | 12500 |
| Net cash (used) provided by investing activities: | (1000) | 190 |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Loans from officer | 257779 | 338831 |
| &nbsp;&nbsp;&nbsp;Repayment of officer loans | (63876) | (92000) |
| &nbsp;&nbsp;&nbsp;Proceeds from convertible notes | 174000 | 25000 |
| &nbsp;&nbsp;&nbsp;Repayment of convertible notes | (10321) | (20860) |
| &nbsp;&nbsp;&nbsp;Advances from other notes payable | 69840 | 116200 |
| &nbsp;&nbsp;&nbsp;Repayments of other notes payable | (161600) | (87745) |
| &nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 265822 | 279426 |
| Net change in cash |  |  |
| Cash - beginning of period | - | - |
| Cash - end of period | $- | $- |
| Supplemental Cash Flow Information: |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $23052 | $54203 |
| &nbsp;&nbsp;&nbsp;Cash paid for income taxes | $- | $- |
| Non Cash Financing and Investing: |  |  |
| &nbsp;&nbsp;&nbsp;Common stock issued for debt modification and penalty | $3500 | $- |
| &nbsp;&nbsp;&nbsp;Sale of Stemsation shares for which proceeds were receivable at period end | $17600 | $- |
| &nbsp;&nbsp;&nbsp;Stemsation shares awarded but not yet issued in settlement of convertible notes receivable | $- | $264000 |
| &nbsp;&nbsp;&nbsp;Reclassification of convertible notes payable to due to officers | $253000 |  |
| &nbsp;&nbsp;&nbsp;Reclassification of other receivable to convertible notes receivable | $33000 | $36363 |

---

See the accompanying notes to the unaudited condensed consolidated financial statements

**NUTRA PHARMA CORP.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**June 30, 2024**

**1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Organization*

Nutra Pharma Corp. ("Nutra Pharma"), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com.

Through its wholly-owned subsidiary, ReceptoPharm, Inc. ("ReceptoPharm"), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin<sup>®</sup>, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin<sup>®</sup>, an over-the-counter pain reliever that is a stronger version of Cobroxin<sup>®</sup> and is designed to treat severe chronic pain. In December 2014, Nutra Pharma launched Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs. In October 2019, Nutra Pharma launched Equine Pain-Away™, an over-the-counter topical pain reliever designed to treat pain and inflammation in horses. In March 2021, Nutra Pharma launched Luxury Feet™, an over-the-counter pain reliever designed specifically to treat foot pain and inflammation especially for women that wear high heels and stilettos. In October of 2021, Nutra Pharma began manufacturing a zeolite detoxifier called Cell Defender for a third party distributor.

*Basis of Presentation and Consolidation*

The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and do not contain certain information included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company's Annual Report on Form 10-K from which the accompanying condensed consolidated balance sheet dated December 31, 2023 was derived.

The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", "us", "we" or "our"). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. The results for the interim period presented are not necessarily indicative of the results that may be expected for the full fiscal year.

*Liquidity and Going Concern*

Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $75,739,547 at June 30, 2024. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $14,640,377 and a stockholders' deficit of $14,558,881 at June 30, 2024.

There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.

We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. The Company's common stock is presently on the OTC Market Group's Expert Market, which means that the Company's common stock is not eligible for proprietary broker-deal quotes. As this limits our ability to raise capital, our plan is to attempt to secure adequate funding through notes payable until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.

The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

*Use of Estimates*

The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with U.S.GAAP which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.

*Revenue from Contracts with Customers*

The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board ("FASB") Accounting Standard Codification ("ASC") Topic 606, *Revenue from Contracts with Customers* ("ASC 606"). Under ASC Topic 606, revenue recognition has a five-step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied.

Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts.

Deferred revenue represents cash received from customers in advance of performance under the contract. Such amounts are recognized as revenue when the related performance obligations are satisfied, which typically occurs upon shipment of the products. All deferred revenue as of the condensed consolidated balance sheet dates are from related parties.

 

*Accounting for Shipping and Handling Costs*

We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales.

*Accounts Receivable and Allowance for Credit Loss*

We grant credit without collateral to our customers based on our evaluation of a particular customer's credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. The Company maintains an allowance for credit losses to reflect the current expected credit losses ("CECL") over the contractual life of the receivables. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable.

Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No allowance for doubtful account is deemed to be required at June 30, 2024 and December 31, 2023.

*Inventories*

Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. We classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of sales. We performed an evaluation of our inventory and related accounts at June 30, 2024 and December 31, 2023, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $30,000 and $20,900, respectively. At June 30, 2024 and December 31, 2023, the total valuation allowance for prepaid venom was $371,472 and $341,472, respectively.

*Financial Instruments*

Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.

 

*Cash and cash equivalents*

The Company maintains cash balances in a non-interest-bearing account that currently does not exceed federally insured limits of $250,000. For the purpose of the condensed consolidated statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. As of June 30, 2024 and December 31, 2023, the Company had no cash or cash equivalents balances.

*Concentration of Credit Risk*

Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. For the three and six months ended June 30, 2024, sales to Avini Health ("Avini"), a related party, accounted for approximately 42% and 44% of total revenues, respectively. For the three and six months ended June 30, 2023, the same customer accounted for approximately 63% and 66% of total revenues, respectively. Avini began manufacturing its own products in September 2023. This shift is expected to significantly reduce our revenues going forward**.** As of June 30, 2024 and December 31, 2023, 100% of the accounts receivable balance are reserves due from one payment processor.

*Operating Lease Right-of-Use Asset and Liability*

The Company accounts for leases in accordance with Accounting Standards Update ("ASU") 2016-02, *Leases* (Topic 842), as amended ("ASC Topic 842"). This standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases.

In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2.

Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company's incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate.

The Company subleases a portion of its leased facility. Sublease rental income is recorded as a reduction of general and administrative expenses in the condensed consolidated statements of operations, as the amounts are considered a recovery of operating costs rather than revenue from the Company's primary operations.

*Derivative Financial Instruments*

Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to other income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.

*Convertible Debt*

The Company adheres to ASU 2020-06, *Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)*. This ASU eliminates certain separation models, including the beneficial conversion feature and cash conversion models, so convertible instruments issued after adoption are generally accounted for as a single liability or equity instrument, unless a conversion feature requires separate derivative accounting under ASC 815. ASU 2020-06 also amends diluted EPS guidance.

*The Fair Value Measurement Option*

We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, *Derivatives and Hedging* ("ASC Topic 815"). The Company reports interest expense, including accrued interest, related to this convertible debt under the fair value option, within the change in fair value of convertible notes and derivatives in the accompanying condensed consolidated statements of operations.

*Derivative Accounting for Convertible Debt and Options and Warrants*

The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, *Derivatives and Hedging*. The conversion terms of some of the convertible notes are variable based on certain factors, such as the future price of the Company's common stock. The number of shares of common stock to be issued is based on the future price of the Company's common stock. The number of shares of common stock issuable upon conversion of the debt is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company's authorized share limit, the equity environment is tainted, and all additional convertible debt and options and warrants are included in the value of the derivative liabilities. Pursuant to ASC 815-15, *Embedded Derivatives*, the fair values of the convertible debt, options and warrants and shares to be issued were recorded as derivative liabilities on the issuance date and revalued at each reporting period.

*Debt Modifications and Extinguishments*

 ****

The Company evaluates amendments, restatements, or other changes to its debt agreements in accordance with ASC 470-50, *Debt — Modifications and Extinguishments*. Under this guidance, we determine whether the revised terms represent a modification of the existing debt or an extinguishment of the old debt and issuance of new debt. If the changes are not deemed substantial, the transaction is accounted for as a modification and any associated fees or costs are amortized over the remaining term of the modified debt. If the changes are determined to be substantial, the original debt is considered extinguished, the new debt is recorded at fair value, and any resulting difference between the carrying amount of the old debt and the fair value of the new debt is recognized in earnings as a gain or loss on extinguishment.

*Property and Equipment*

Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.

*Long-Lived Assets*

The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets.

*Income Taxes*

The Company recorded no income tax expense for the three and six months ended June 30, 2024 and 2023 because the estimated annual effective tax rate was zero. The Company applies the asset and liability method of accounting for income taxes, under which deferred tax assets and liabilities are recognized for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, as well as for net operating loss and tax credit carryforwards. Deferred tax assets are reduced by a valuation allowance when, based on available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

As of June 30, 2024, the Company continues to maintain a full valuation allowance against its net deferred tax assets due to a history of operating losses and the uncertainty regarding the Company's ability to generate sufficient future taxable income to realize such assets.

*Stock-Based Compensation*

We account for stock-based compensation in accordance with FASB ASC Topic 718, *Stock Compensation* ("ASC Topic 718") which requires that the cost resulting from all share-based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.

 

*Net Income (Loss) Per Share*

Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, *Earnings per Share*. Basic income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of conversion options and warrants would come from newly issued common shares from our remaining authorized shares.

The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because for the three and six months ended June 30, 2024 and 2023, the effect of including these potential shares was antidilutive due to a net loss:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2024** | **June 30, 2023** |
| Convertible notes payable at fair value | 19537028972 | 18094916348 |
| Convertible notes payable | 6979649502 | 6364577169 |
| Total | 26516678474 | 24459493517 |

---

*Recent Accounting Pronouncements*

*Adopted Pronouncements*

As of January 1, 2024, the Company adopted ASU No. 2023-07, *Codification Improvements to Segment Reporting (Topic 280)* ("ASU 2023-07"), which provides clarifications and improvements to the existing segment reporting requirements, including updates related to the aggregation criteria, reconciliation of segment measures to consolidated financial statements, and disclosure requirements. The adoption did not have a material effect on the accompanying condensed consolidated financial statements.

*Not Yet Effective Pronouncements*

The Company has evaluated the impact of the following recently issued accounting standards, which have not yet been adopted as of June 30, 2024:

ASU No. 2023-09, *Improvements to Income Tax Disclosures (Topic 740)* ("ASU 2023-09"), which enhances the existing income tax disclosure requirements by requiring greater disaggregation within the effective tax rate reconciliation and expanded information regarding income taxes paid by jurisdiction. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the adoption of this ASU to have a material effect on the accompanying condensed consolidated financial statements.

All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

**2. FAIR VALUE MEASUREMENTS**

Certain assets and liabilities that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 are measured in accordance with FASB ASC Topic 820-10-05, *Fair Value Measurements*. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the condensed consolidated financial statements.

The statement requires fair value measurement be classified and disclosed in one of the following three categories:

---

| | |
|:---|:---|
| Level 1: | Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; |
| Level 2: | Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and |
| Level 3: | Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). |

---

The following table summarizes our financial instruments measured at fair value at June 30, 2024 and December 31, 2023:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fair Value Measurements at June 30, 2024** | **Fair Value Measurements at June 30, 2024** | **Fair Value Measurements at June 30, 2024** | **Fair Value Measurements at June 30, 2024** |
|  | **Total** | **Level 1** | **Level 2** | **Level 3** |
| **Liabilities:** |  |  |  |  |
| Derivative liabilities | $697965 | $- | $697965 | $- |
| Convertible notes at fair value | $1953704 | $- | $- | $1953704 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fair Value Measurements at December 31, 2023** | **Fair Value Measurements at December 31, 2023** | **Fair Value Measurements at December 31, 2023** | **Fair Value Measurements at December 31, 2023** |
|  | **Total** | **Level 1** | **Level 2** | **Level 3** |
| **Liabilities:** | | | | |
| Derivative liabilities | $661257 | $- | $661257 | $- |
| Convertible notes at fair value | $1867421 | $- | $- | $1867421 |

---

The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the six months ended June 30, 2024 and the year ended December 31, 2023:

---

| | | |
|:---|:---|:---|
| **Description** | **June 30,**<br> **2024** | **December 31,**<br> **2023** |
| Beginning balance | $- | $6072 |
| Purchases, issuances, and settlements |  |  |
| Total gain included in earnings (1) | - | (6072) |
| Ending balance | $- | $- |

---

(1) The
 gain related to the revaluation of our warrant liability is included in "Change in fair value of convertible notes and derivatives"
 in the accompanying unaudited condensed consolidated statements of operations.

We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 4.85% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 620%, (4) zero expected dividends, (5) exercise price set forth in the agreements, (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted.

We valued derivative liabilities using the number of potential convertible shares for warrants in equity and convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at June 30, 2024. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company's authorized share limit and the equity environment is tainted, and therefore all convertible debt and options and warrants should be accounted for as liabilities.

The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at June 30, 2024 and December 31, 2023:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | | | **Conversion Price - Lower of**<br> **Fixed**<br> **Price or Percentage of VWAP**<br> **for Look-back Period** | **Conversion Price - Lower of**<br> **Fixed**<br> **Price or Percentage of VWAP**<br> **for Look-back Period** | **Conversion Price - Lower of**<br> **Fixed**<br> **Price or Percentage of VWAP**<br> **for Look-back Period** |
| <br>**Debenture** |<br>**Face<br> Amount** | <br>**Interest<br> Rate**  | <br>**Default<br> Interest<br> Rate**  | <br>**Discount<br> Rate**  | **Anti-Dilution<br> Adjusted<br> Price**  | **% of stock price for look-back period** | **Look-back<br> Period**  |
| June 30, 2024 | $663529 | 8%-10% | 19%-24% | N/A | $0.00005-$0.00006 | 50%-60% | 3 to 25 Days |
| December 31, 2023 | $663529 | 8%-10% | 19%-24% | N/A | $0.00005-$0.00006 | 50%-60% | 3 to 25 Days |

---

Using the stated assumptions summarized in the table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2024 and the year ended December 31, 2023:

---

| | | |
|:---|:---|:---|
| **Description** | **June 30,**<br> **2024** | **December 31,**<br> **2023** |
| Beginning balance | $1867421 | $1729183 |
| Loss from change in fair value (1) | 86283 | 146155 |
| Repayments in cash |  | (5417) |
| Conversion to common stock | - | (2500) |
| Ending balance | $1953704 | $1867421 |

---

(1) The
 losses related to the valuation of the convertible notes are included in "Change in fair value of convertible notes and derivatives"
 in the accompanying unaudited condensed consolidated statements of operations.

**3. INVENTORIES**

Inventories are valued at the lower of cost or net realizable value on an average cost basis. At June 30, 2024 and December 31, 2023, inventories were as follows:

---

| | | |
|:---|:---|:---|
|  | **June 30,<br> 2024** | **December 31,**<br> **2023** |
| Raw Materials | $131670 | $135670 |
| Finished Goods | 6760 | 9044 |
| Total Inventories | 138430 | 144714 |
| Less: Long-term inventory | (114670) | (125170) |
| Current portion | $23760 | $19544 |

---

**4. PROPERTY AND EQUIPMENT**

Property and equipment consists of the following at June 30, 2024 and December 31, 2023:

---

| | | |
|:---|:---|:---|
|  | **June 30,<br> 2024** | **December 31, <br> 2023** |
| Furniture and fixtures | $20805 | $20805 |
| Lab equipment | 37204 | 37204 |
| Total | 58009 | 58009 |
| Less: Accumulated depreciation | (43887) | (40167) |
| Property and equipment, net | $14122 | $17842 |

---

During 2023, the Company sold certain equipment to Avini, a related party, in connection with Avini assuming responsibility for the manufacturing of its own products. The equipment had a carrying amount of approximately $43,900 at the time of sale.

We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At June 30, 2024, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the three-months ended June 30, 2024 and 2023 was $1,860 and $5,442, respectively. Depreciation expense for the six-months ended June 30, 2024 and 2023 was $3,720 and $10,886, respectively.

**5. DUE TO/FROM OFFICERS**

At June 30, 2024, the balance due to Rik Deitsch, the Company's former CEO, and the companies majority owned and controlled by him (collectively referred to as "Due to Officer") in the aggregate is $855,375, which balance is unsecured and accruing interest at 4%. During the six months ended June 30, 2024, in the aggregate, we repaid $63,876 and were advanced $257,779 on this balance. Additionally, accrued interest on the outstanding balance was $11,201 and is included in the due to officer account. The Company had fully reserved receivables from companies owned by him. The reserve was $177,261 as of June 30, 2024. No bad debt expense was recorded for the three and six months ended June 30, 2024. The bad debt expense of $0 and $105,465 was recorded for the three and six months ended June 30, 2023, respectively.

During March 2024, upon the appointment of Michael Flax as the Company's Chief Executive Officer, the Company reclassified convertible notes payable totaling $253,000 with original issuance discounts of $33,000, which were issued during 2021 and 2022, to due to officer. The notes bear a conversion price of $0.0008 per share and have a contractual maturity of one year from their respective funding dates. The notes are currently in default.

At December 31, 2023, the balance due to Rik Deitsch, the Company's former CEO, and the companies majority owned and controlled by him in the aggregate is $659,433, which balance is unsecured and accruing interest at 4%. During the year ended December 31, 2023, in the aggregate, we repaid $162,100 and were advanced $599,500 on this balance. Additionally, accrued interest on the outstanding balance was $9,161 and is included in the due to officer account. The Company had fully reserved receivables from companies owned by the Company's former CEO. The reserve was $177,261 as of December 31, 2023.

These transactions were not conducted on an arm's-length basis and, as such, may differ from the terms that would have been negotiated with an unrelated third party.

**6. DEBTS**

Debts consist of the following at June 30, 2024 and December 31, 2023:

---

| | | |
|:---|:---|:---|
|  | **June 30,<br> 2024** | **December 31,**<br> **2023** |
| Notes payable – Unrelated third parties (Net of discount of $14,980 and $14,350, respectively) (1) | $1222872 | $1280702 |
| Convertible notes payable – Unrelated third parties (Net of discount of $40,270 and $17,814, respectively) (2) | 4908175 | 4948678 |
| Convertible notes payable, at fair value (3) | 1953704 | 1867421 |
| Other advances from an unrelated third party (4) | 225000 | 225000 |
| SBA notes payable (5) | 149900 | 149900 |
| Ending balances | 8459651 | 8471701 |
| Less: Long-term portion- SBA notes payable | (141950) | (143657) |
| Current portion | $8317701 | $8328044 |

---

(1) At
 June 30, 2024 and December 31, 2023, the balance of $1,222,872 and $1,280,702 net of discount of $14,980 and $14,350 , respectively,
 consisted of the following loans:

● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The Notes carry interest at 12 % annually and were originally due on the date that was six-months from the execution and funding of the note. The notes were convertible into shares of Company's common stock at a conversion price of $0.008 per share. At June 30, 2024 and December 31, 2023, we owed principal balance of $91,156 , and accrued interest of $79,157 and $73,733 , respectively. The remaining principal balance of $91,156 and accrued interest of $79,157 are subject to litigation and a settlement was reached in May 2025 (See Note 12 and Note 14).

● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. ("LPR"), we agreed to pay LPR a total of $350,000 in monthly instalments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. We signed the first amendment to the settlement agreement where we agreed to pay $175,000 , which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 30, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). LPR sold the note to Southridge Partners, LLP ("Southridge") for consideration of $281,772 in June 2012. In August 2013, the debt of $281,772 reverted back to LPR and remains outstanding at June 30, 2024 and December 31, 2023.

● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge. The debt of $55,410 reverted back to University Centre West Ltd. and is currently outstanding and carries no interest.

● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10 % annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2024 and December 31, 2023, the accrued interest is $8,313 and $7,811 , respectively.

● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2 %. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000 . The note is in default and in negotiation of settlement. At June 30, 2024 and December 31, 2023, the outstanding principal balance is $50,000 and accrued interest is $104,700 and $98,667 , respectively.

● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2 %. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2024 and December 31, 2023, the outstanding principal balance is $50,000 and accrued interest is $97,900 and $91,867 , respectively.

● A promissory note originally issued to an unrelated third party in August 2016 was restated in September 2019 in the amount of $333,543 bearing monthly interest at a rate of 2.0 % and was due September 2020. The Note is in default and negotiation of settlement. At June 30, 2024 and December 31, 2023, the principal balance is $333,543 , and the accrued interest is $390,245 and $349,997 , respectively.

● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10 % annually. The note was due in one year from the execution and funding of the note. In March 2018, $15,000 of the principal balance of the note was assigned to an unrelated third party and is in negotiation of settlement. In January 2019, the remaining principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). At June 30, 2024 and December 31, 2023, the principal balance outstanding is $15,000 , and the accrued interest is $1,371 .

● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2 %. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2024 and December 31, 2023, the accrued interest is $94,200 and $88,167 , respectively.

● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10 % annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2024 and December 31, 2023, the accrued interest is $8,914 and $8,285 , respectively.

● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15 % annum. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000 , respectively, with the monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. The Company repaid an aggregate of $136,527 over the four years from 2018 through 2021. The portion of settlement of $130,401 was repaid in full as of June 30, 2021. At June 30, 2024 and December 31, 2023, the outstanding principal balance is $33,874 , and is in default and negotiation of settlement.

● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000 . The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2024 and December 31, 2023, the principal balance of the note is $50,000 .

● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000 . During March 2020, $50,000 of the Note was settled for 125,000,000 shares with a fair value of $87,500 . We recorded a loss on settlement in other expense for $37,500 in March 2020. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $32,200 . The remaining balance of $70,000 was restated with additional issuance discount of $14,000 . We repaid a total of $15,000 during the first and fourth quarters of 2022. At June 30, 2024 and December 31, 2023, the principal balance of the loan is $69,000 , and is in default and negotiation of further settlement.

● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000 . The note is in default and in negotiation of settlement. The note was due in six months from the execution and funding of the note. At June 30, 2024 and December 31, 2023, the principal balance of the note is $18,000 and the accrued interest is $2,000 . The accrued interest represents a one-time amount and no further interest is accruing on the note.

● In October 2022, the Company received a loan for $199,000 from a non-related party. The loan was repaid in full in November 2024 (see Note 14), together with interest at an average annual rate of approximately 51 %. Weekly payments ranged from approximately $2,000 to $3,800 ; due to our financial hardship, the lender periodically reduced the payment amounts to provide temporary relief. The Company has recorded loan costs in the amount of $2,488 for the loan's origination fees paid at inception date. The total loan cost is amortized over the term of the loan. The loan is under personal guarantee by Mr. Deitsch. We repaid $15,100 and $78,261 during the years ended December 31, 2023 and 2022, respectively, and an additional $41,788 during the first two quarters of 2024. At June 30, 2024 and December 31, 2023, the principal balance, is $63,851 and $105,639 , respectively. The amortization of loan cost for three and six months ended June 30, 2023 is $0 and $1,200 , respectively.

● In December 2022, a promissory note of $17,000 was issued to an unrelated third party, scheduled to be repaid through monthly payments of $1,518 with interest at an average annual rate of 12.99 %. In February 2023, the Company issued a $25,000 promissory note to the same party, using the proceeds to fully repay the December 2022 loan. Although structured for repayment in 12 monthly installments, the note was settled in full ahead of schedule in July 2023. At that time, the Company issued a new $32,000 promissory note to the same party, with the proceeds applied to retire the February 2023 note. The July 2023 note was repaid in August 2023 in connection with the issuance of a $34,000 promissory note, which was fully repaid in September 2024. Total interest expense was $603 and $1,114 for the three months ended June 30, 2024 and 2023, respectively. Total interest expense was $1,206 and $1,396 for the six months ended June 30, 2024 and 2023, respectively. At June 30, 2024 and December 31, 2023, the principal balance of the loan is $8,506 and $25,492 , respectively.

● In June 2023, the Company entered into a Purchase and Sale of Future Receipts Agreement with an unrelated third party. Pursuant to the agreement, the buyer purchased $135,850 of the Company's future receivables for total proceeds of $91,200 , on a non-recourse basis. Under the terms of the agreement, the Company authorized the buyer to debit amounts directly from its bank account at a specified remittance frequency until the total purchased amount of $135,850 was fully collected. In connection with the transaction, the Company recorded a total debt discount of $44,650 , representing loan origination fees and issuance costs, which was amortized over the term of the agreement. The Company repaid $92,184 during the second through fourth quarters of 2023. The remaining balance of $43,666 under this agreement was fully repaid in February 2024 in connection with the execution of a subsequent agreement. Amortization of the debt discount for the three and six months ended June 30, 2024 was $0 and $14,350 , respectively. Amortization of the debt discount for the three and six months ended June 30, 2023 was $2,550 . As of June 30, 2024 and December 31, 2023, the principal balance, net of unamortized debt discount of $0 and $14,350 , was $0 and $29,316 , respectively.

● In February 2024, the Company entered into a second Purchase and Sale of Future Receipts Agreement with the same third party. Under this agreement, the buyer purchased $104,400 of the Company's future receivables for total proceeds of $72,000 , on a non-recourse basis. The Company authorized the buyer to debit its bank account at the specified remittance frequency until the full purchased amount of $104,400 was remitted. In connection with this second transaction, the Company recorded a total debt discount of $34,560 for loan origination fees and issuance costs, which was amortized over the term of the agreement. The outstanding balance under this agreement was fully repaid in September 2024. During the first two quarters of 2024, we repaid $59,160 . Amortization of the debt discount for the three and six months ended June 30, 2024 was $14,970 and $19,580 . As of June 30, 2024, the principal balance, net of an unamortized debt discount of $14,980 , was $30,260 .

(2) At
 June 30, 2024 and December 31, 2023, the balance of $4,908,175 and $4,948,678 net of discount of $40,270 and $17,814 , respectively,
 consisted of the following convertible loans:

● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000 and a conversion option at $0.001 per share. The note was due in six months from the execution and funding of the note. The loan is in default and in negotiation of settlement. At June 30, 2024 and December 31, 2023, the principal balance of the note is $60,000 .

● During January through December 2018, we issued convertible notes payable to 14 unrelated third parties for a total of $525,150 with original issue discount of $44,150 . The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company's common stock at a conversion price ranging from $0.0003 to $0.001 per share. During May 2019, we restated two convertible notes payable with additional original issuance discount of $6,400 . The two restated notes were due in August 2020 and are in default. At June 30, 2024 and December 31, 2023, the outstanding principal balance of the notes issued in 2018 was $531,550 .

● During February 2019, the Company issued convertible notes payable totaling $55,000 with an original issuance discount of $5,000 . The notes are convertible into shares of the Company's common stock at a conversion price of $0.0005 per share. During August and October 2020, the notes were amended to include additional original issuance discounts of $9,200 and were accompanied by the issuance of warrants. All warrants associated with these notes expired during 2022. The Notes are in default and negotiation of settlement.

● During November 2019, we issued a convertible promissory note to an unrelated third party for $137,500 with original issuance discount of $12,500 . The note was due nine months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.000275 . The Note is in default and negotiation of settlement.

 At June 30, 2024 and December 31, 2023, the outstanding principal balance of the notes issued in 2019 was $201,700 .

● During the year ended December 31, 2020, the Company issued convertible notes payable of $555,600 with an original issuance discount of $53,600 . $287,400 of these notes were due in a year, and $268,200 of the Notes were due in six months from the execution and funding of each note. The notes are convertible into shares of the Company's common stock at a conversion price ranging from $0.0002 to $0.0008 per share. In May 2022, $16,500 of the notes issued in November 2020 were settled through the issuance of common stock. At June 30, 2024 and December 31, 2023, the outstanding principal balance of the notes issued in 2020 was $539,100 . The notes are currently in default and under negotiation for settlement.

● During 2021, we issued convertible promissory notes to unrelated third parties totaling $2,480,043 with original issuance discounts of $323,484 . The Noteholders had the right to convert the notes into shares of Common Stock at a conversion price ranging from $0.0003 to $0.002 per share. The notes were due one year from the execution and funding of the notes. On January 1, 2022, $228,563 of the Notes issued during January to April 2021 were amended to extend the due date to August 29, 2022. The notes are currently in default and under negotiation for settlement.

● During March 2021, the remaining balance of the promissory note of $30,000 originally issued in September 2018 was sold to an unrelated third party in the form of a convertible note at a fixed conversion price of $0.01 per share. The new note carries interest at 12 % with scheduled monthly payments of $1,000 beginning in April 2021 through March 2024. The Note was repaid in full during the first quarter of 2024. The principal balance as of June 30, 2024 and December 31, 2023 is $0 and $2,821 . The interest expense for the three months ended June 30, 2024 and 2023 is $0 and $280 , respectively. The interest expense for the six months ended June 30, 2024 and 2023 is $26 and $640 , respectively.

● During August 2021, the promissory note of $166,926 was restated in the form of a convertible note at a fixed conversion price of $0.002 per share. The restated balance is $183,619 with an original issuance discount of $16,693 and was due February 2022. During February 2022, we issued 20,866,250 shares of common stock to satisfy the principal balance of $16,693 . The remaining balance of $166,926 was further restated into a convertible note with a fixed conversion price of $0.002 per share, maturing in August 2022. In August 2022, the balance of $166,926 was further restated with an original issuance discount of $16,693 in the form of a convertible note at a fixed conversion price of $0.002 per share due February 2023, provided that our agreement to repay $16,693 in cash by October 2022. However, we failed to meet this repayment obligation. As a result, the new convertible note amounts to a total of $200,312 (including $166,926 , $16,693 , and an original issuance discount of $16,693) with a fixed conversion price of $0.002 per share, due February 2023. The Company made a payment of $5,000 , which was applied against accrued late payment penalties. As of December 31, 2023, the note had a principal balance of $200,312 and an accrued late payment penalty of $24,608 , resulting in a total outstanding balance of $224,920 . In February 2024, the principal balance and the related penalty were restated. 35,000,000 shares of common stock were issued in satisfaction of $24,920 of the outstanding balance (See Note 7), with the remaining $200,000 restated as new principal. The fair value of the shares issued was $3,500 , resulting in a gain of $21,420 , which was recognized as a gain on settlement of debt and accrued expense in the accompanying condensed consolidated statements of operations for the first quarter of 2024. Amortization for the three and six months ended June 30, 2024 was $7,500 and $12,500 , respectively, for the three and six months ended June 30, 2023 was $0 and $3,467 , respectively. In addition, a 15 % OID was applied to the new principal, resulting in a restated principal balance of $230,000 . The restated note was due in February 2025 and remained convertible at a fixed price of $0.0008 per share. As of June 30, 2024, the principal balance, net of an unamortized debt discount of $17,500 , was $212,500 . In February 2025, the note was further restated, with the principal balance of $230,000 subject to an additional 15 % OID, while maintaining the same fixed conversion price of $0.0008 . The note continues to be secured by a personal guarantee.

● During 2022, we issued convertible promissory notes to unrelated third parties totaling $874,000 with original issuance discounts of $114,000 . The noteholders have the right to convert the notes into shares of common stock at conversion prices ranging from $0.0005 to $0.0008 per share, and the notes were due one year from their respective execution and funding dates. The notes are currently in default and under negotiation for settlement.

● During 2022, the convertible promissory notes for a total of $339,825 were amended to add additional original issuance discount for a total of $50,974 and matured in July 2023. The notes are currently in default and under negotiation for settlement.

● During 2022, the Company settled a total of $143,000 of convertible promissory notes, of which $108,500 was settled through the issuance of shares of common stock, with the remaining balance repaid in cash.

● In February and November 2023, the Company settled two convertible notes which had a conversion price of $0.0008 , with total cash payments of $7,250 , resulting in a $350 loss on settlement during the first quarter of 2023.

● In March 2023, the Company repaid $5,000 of its outstanding convertible promissory notes of $52,500 originated in September 2021.

● During the third quarter of 2023, the Company settled convertible promissory notes of $11,500 , which had a conversion price of $0.002 . The Company completed repayment in the fourth quarter of 2023, with $13,000 in cash repayments.

● During 2023, the Company amended convertible promissory notes totaling $197,025 to add aggregate original issuance discounts of $29,554 , which extended the due dates by twelve months, to various dates in January, May, and July 2024. The notes are currently in default and under negotiation for settlement.

● During 2023, the Company issued convertible promissory notes to unrelated third parties with a fixed conversion price of $0.0006 per share, issued during the first, third, and fourth quarter, totaled $146,338 with a combined original issuance discount of $19,088 . Of these, $17,250 of the notes issued in the fourth quarter were under a personal guarantee. All notes are due one year from their respective execution and funding dates. The notes are currently in default and under negotiation for settlement.

● During the first quarter of 2024, a convertible promissory note of $53,230 was amended to add an additional original issuance discount of $7,985 scheduled to expire in January 2025.

● During the first quarter of 2024, the Company issued convertible promissory notes to unrelated third parties with a fixed conversion price ranging from $0.0005 to $0.0006 per share, totaled $128,800 with a combined original issuance discount of $16,800 . The notes were due one year from their respective execution and funding dates.

● During the second quarter of 2024, the Company issued convertible promissory notes to unrelated third parties with a fixed conversion price ranging from $0.0005 to $0.0006 per share, totaled $71,300 with a combined original issuance discount of $9,300 . The notes were due one year from their respective execution and funding dates.

● During the second quarter of 2024, the Company settled convertible promissory notes of $52,500 , which had a conversion price of $0.002 . The Company completed repayment in the second quarter of 2025, with $60,000 in cash repayments, recognizing a $7,500 loss on settlement of debt during the second quarter of 2024 which is included in loss on settlement of debt in the accompanying condensed consolidated statements of operations.

● At June 30, 2024, $4,239,923 of the above mentioned convertible notes payable are in default and negotiation of settlement. At the date of this report, $4,718,444 of the notes remain in default and in negotiation of settlement.

● The total discount amortization on all notes for the three months ended June 30, 2024 and 2023 was $23,102 and $27,692 , respectively. The total discount amortization on all notes for the six months ended June 30, 2024 and 2023 was $41,630 and $84,836 , respectively. At June 30, 2024 and December 31, 2023, the carrying value of the notes was $4,908,175 and $4,948,678 , net of unamortized discounts of $40,270 and $17,814 , respectively.

(3) At
 June 30, 2024 and December 31, 2023, the balance of $1,953,704 and $1,867,421 , respectively, consisted of the following convertible
 loans:

● The balance of $20,000 of a Convertible Note originated in March 2016 is in default and negotiation of settlement. The conversion price is equal to 55 % of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. We have accrued interest at a default interest rate of 20 % after the note's maturity date. At June 30, 2024 and December 31, 2023, the convertible notes payable with principal balance of $20,000 plus accrued interest of $31,305 and $29,294 at fair value, were recorded at $93,283 and $89,626 , respectively. The Note is in default and negotiation of settlement.

● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note was due on May 4, 2018 . The Note holder has the right to convert the note into shares of Common Stock at sixty percent (60 %) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. We have accrued interest at a default interest rate of 19 % after the note's maturity date. After prior conversions, at June 30, 2024 and December 31, 2023, the remaining principal of $12,629 plus accrued interest of $21,148 and $19,885 , respectively, at fair value, was recorded at $56,296 and $54,191 , respectively. The remaining principal balance of the Note is in default.

● During October 2020, we issued a Convertible Debenture in the amount of $250,000 to an unrelated third party. The note was due in October 2021. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. Upon default, we increased the outstanding principal by 10 % and began accruing interest at the default rate of 24 % from the note's maturity date. At June 30, 2024 and December 31, 2023, the convertible note payable with principal balance of $275,000 plus accrued interest of $197,386 and $164,657 , respectively, at fair value, were recorded at $944,773 and $879,315 . The Note is in default and negotiation of settlement.

● During July 2018, we issued a convertible debenture in the amount of $50,000 to an unrelated third party, and during August 2018, we issued a convertible debenture in the amount of $20,000 to an unrelated third party. Both notes carry interest at 8 % and were due one year from issuance, unless previously converted into shares of restricted common stock. Following maturity, we accrued interest at the default rate of 24 %. The noteholders have the right to convert the notes into shares of common stock at fifty-five percent of the average of the three lowest trading prices of our restricted common stock for the fifteen trading days including the date of receipt of the conversion notice. At June 30, 2024 and December 31, 2023, the combined convertible notes payable plus accrued interest of $88,153 and $79,868 , respectively, were recorded at fair value of $287,552 and $272,489 . The Note is in default and negotiation of settlement.

● During January 2019, we issued a convertible denture in the amount of $75,900 to an unrelated third party. The note was due in one year from the restatement date of the note. During November 2020, the Note holder assigned $20,000 of the $75,900 convertible note in January 2019 to a third party. The Noteholder has the right to convert the note into shares of common stock at 50 % discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion.

 At June 30, 2024 and December 31, 2023, the convertible note payable of $55,900 , at fair value, was recorded at $111,800 . The note was due January 2020. The Note is in default and negotiation of settlement.

● During June 2019, we issued a convertible promissory note to an unrelated third party for $240,000 with original issuance discount of $40,000 . The note was due one year from the execution and funding of the notes. In connection with the issuance of this note, we issued 16,000,000 shares of our restricted common stock. The common stock was valued at $4,688 and recorded as a debt discount that was amortized over the life of the note. The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion. During October 2022, repayment of $10,000 was made. At June 30, 2024 and December 31, 2023, the convertible note payable with principal balance of $230,000 , at fair value, was recorded at $460,000 . The Note is in default and negotiation of settlement.

(4) At
 June 30, 2024 and December 31, 2023, the balance of $225,000 consisted of the advances received from a third party during the periods
 from May 2019 through May 2020 in connection with a Joint Venture proposal. The deposits were considered as payments towards the
 purchase of equity in the joint venture. The joint venture is currently on hold.

(5) During
 June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster
 Loan assistance program (the "EIDL Loan") considering the impact of the COVID-19 pandemic on the Company's business.
 Pursuant to the Loan Authorization and Agreement (the "SBA Loan Agreement"), the principal amount of the EIDL Loan was
 $150,000 , with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75 % per annum. Installment payments,
 including principal and interest, in the amount of $731 commenced in February 2023. The balance of principal and interest is payable
 over a 360-month period from the date of the SBA Loan Agreement. The SBA requires that the Company collateralize the loan to the
 maximum extent up to the loan amount. If business fixed assets do not "fully secure" the loan the lender may include
 trading assets (using 10% of current book value for the calculation), and must take available equity in the personal real estate
 (residential and investment) of the principals as collateral. During 2023, total repayments of $10,234 were made and applied to accrued
 interest. During the first and second quarter of 2024, repayment of $2,924 were made and applied to accrued interest. Interest expense
 was $1,406 for each of the three months ended June 30, 2024 and 2023, and $2,812 for each of the six months ended June 30, 2024 and
 2023. The outstanding balance for the EIDL loan at June 30, 2024 and December 31, 2023 is $149,900 . The accrued interest as of June
 30, 2024 and December 31, 2023 loan is $9,810 and $9,920 , respectively.

At June 30, 2024, the future minimum principal payments for all debts are as follows:

SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT

---

| | |
|:---|:---|
| June 30, | Amount |
| 2025 | $8317701 |
| 2026 | 3505 |
| 2027 | 3639 |
| 2028 | 3777 |
| 2029 | 3922 |
| Thereafter | 127107 |
|  | $8459651 |
| Less: Long-term portion |  |
| SBA notes payable | (141950) |
| Current portion | $8317701 |

---

**7. STOCKHOLDERS' DEFICIT**

Series B Preferred Stock

Effective March 2021, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination for its Series B Preferred Stock. The Series B Preferred Stock has a par value of $0.001 per shares and consists of 12,000,000 shares.

Terms of the Series B Preferred include the following:

&nbsp;&nbsp;&nbsp;&nbsp;1. The
 Series B Preferred votes with the Company's common stock as a single class on all matters or consents for the Company's
 common stockholders. Each share of Series B Preferred is entitled to one thousand votes per share.

2. The
 Series B Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders
 of outstanding shares of common stock, in which event, each outstanding share of the Series B Preferred will be entitled to receive
 dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of
 common stock. Any dividend payable to the Series B Preferred will have the same record and payment date and terms as the dividend
 payable on the common stock.

3. Upon
 any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series B Preferred
 then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an
 amount in cash equal to $0.133 in cash per share before any distribution is made on any shares of the Company's common stock.
 If upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the application of all amounts available
 for payments with respect to Series B Preferred would not result in payment in full of Series B Preferred, the holders shall share
 equally and ratably in any distribution of assets of the Company in proportion to the full liquidation preference to which each is
 entitled.

4. The
 Series B Preferred does not have any redemption rights.

During November 2021, the Board of Directors approved resolutions for the issuance of a total of 9,000,000 shares of Series B Preferred stock to Mr. Deitsch to discharge $540,000 of his accrued salary. The shares were valued at the accrued payable amount by agreement of the parties.

Effective November 15, 2021, the Board of Directors authorized an exchange of 3,000,000 shares of Series A Preferred Stock held by Mr. Deitsch for an equal number of Series B Preferred Stock.

Common Stock Issued for Debt Modification and Penalty

During February 2024, we issued 35,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $200,312 amended in August 2022. The shares were valued at a fair value of $3,500 (See Note 6).

**8. STOCK WARRANTS**

Common Stock Warrants

During January and May 2022, in connection with the issuance of the convertible note of $115,000 with original issuance discount of $15,000 due in one year, the Company granted the 164,285,714 warrants at an exercise price of $0.002 per share that expire one year from the date of issuance. As of May 2023, all of these warrants had expired.

A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2023 and the six months ended June 30, 2024:

---

| | | |
|:---|:---|:---|
|  | **Number Of**<br>**shares** | **Weighted average**<br>**exercise price** |
| Balance December 31, 2022 | 164285714 | $0.002 |
| Exercised |  |  |
| Issued |  |  |
| Expired | (164285714) | 0.002 |
| Balance December 31, 2023 |  | $- |
| Exercised |  |  |
| Issued |  |  |
| Expired | - | - |
| Balance June 30, 2024 | - | $- |

---

The following table summarizes information about fixed-price warrants outstanding as of June 30, 2024 and December 31, 2023**:**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Exercise Price** | **Weighted Average Number Outstanding** | **Weighted Average Contractual Life** | **Weighted Average Exercise**<br> **Price** |
| June 30, 2024 | $- | - | - | $- |
| December 31, 2023 | $- | 33082192 | 0 years | $- |

---

**9. ACCRUED EXPENSES**

Accrued expenses consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **June 30,<br> 2024** | **December 31,<br> 2023** |
| Accrued consulting fees | $275900 | $220900 |
| Accrued settlement expenses (1) | 680235 | 680235 |
| Accrued payroll taxes | 250166 | 240023 |
| Accrued interest | 796611 | 756426 |
| Accrued others | 2913 | 2913 |
| Total | $2005825 | $1900497 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) On
 August 28, 2024, the U.S. District Court for the Eastern District of New York entered a final consent judgment against the Company,
 enjoining it from violating certain provisions of the federal securities laws and ordering disgorgement and civil monetary penalties.
 The Court entered a final consent judgment in which it was ordered to pay $520,940 in disgorgement and $59,295 in prejudgment interest
 thereon, as well as $100,000 in civil penalties. As of June 30, 2024 and December 31, 2023, the Company had accrued a total legal
 settlement amount of $680,235 (See Note 12 and Note 14).

**10. PREPAID EXPENSES**

Prepaid expenses and other current assets consist of the following:

---

| | | |
|:---|:---|:---|
|  | **June 30,<br> 2024** | **December 31,<br> 2023** |
| Supplier advances for future purchases | $371472 | $341472 |
| Reserve for supplier advances | (371472) | (341472) |
| Net supplier advances |  |  |
| Prepaid professional fees | 33999 | 29999 |
| Total | $33999 | $29999 |

---

We performed an evaluation of our inventory and related accounts at June 30, 2024 and December 31, 2023, and increased the reserve on supplier advances for future venom purchases by $30,000 and $20,900, respectively.

**11. CONVERTIBLE NOTES RECEIVABLE**

During March through November 2021, we purchased five convertible notes from StemSation International (the "StemSation") for a total of $286,550 with original issuance discount of $26,050. The notes are convertible into common shares for $0.01 per common share and mature in one year from the funding of the notes. The original issuance discount is amortized over the lives of notes.

From March to December 2022, we purchased six convertible notes from StemSation totaling $41,196, which included a $3,745 original issuance discount. Repayments of $101,750 have been received during the third and fourth quarter of 2022. At December 31, 2022, the principal balance of the notes, net of discount of $600 was $225,396.

During March through June 2023, we purchased additional convertible notes for a total of $50,504 which included a $1,831 original issuance discount.

All the notes mature one year after funding. The notes are convertible into common shares at $0.01 per share, except for those issued in December 2022 ($6,600) and March through June 2023 ($50,504) are convertible at $0.005 per share. The original issuance discount is amortized over the lives of the notes. Repayments of $12,500 have been received during the first and second quarter of 2023.

The principal balance of the notes prior to settlement was $264,000. On June 5, 2023, the Company entered into a settlement agreement with StemSation to convert the notes receivable balances of $264,000 into shares of StemSation's common stock at $0.00176 per share. The settlement agreement was approved on June 15, 2023 by the Circuit Court.

Pursuant to the agreement, the Company is entitled to receive 150,000,000 shares of StemSation's common stock in exchange for the full settlement of the outstanding notes receivable. As of June 30, 2023, the Company recognized the settlement receivable at $264,000, equal to the carrying amount of the notes receivable exchanged. Accordingly, the convertible notes receivable were derecognized.

Between July and November 2023, $103,916 of the $264,000 settlement was converted into 59,043,425 shares, as summarized in the table below. The remaining $160,084 of the settlement was recorded as a settlement receivable in the accompanying condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023 and is expected to be converted in subsequent periods.

---

| | | | |
|:---|:---|:---|:---|
| **Date of Conversion Notice** | **Conversion Amount** | **Number of Shares Issued** | **Value of Shares Issued<br> ($/per share) at Issuance** |
| 7/12/2023 | $33516 | 19043425 | 0.00176 |
| 8/24/2023 | $35200 | 20000000 | 0.00176 |
| 11/7/2023 | $35200 | 20000000 | 0.00176 |

---

Of the 59,043,425 shares issued, 39,043,425 shares were sold in the third quarter of 2023 for total proceeds of $68,716, of which $33,516 was collected and $35,200 remained receivable as of December 31, 2023. The remaining 20,000,000 shares converted in November 2023, valued at $35,200, were recorded as an investment in StemSation stock at cost.

In March 2024, the Company sold an additional 10,000,000 shares for $17,600, which remained outstanding as of June 30, 2024. As a result, the total receivable balance was $52,800 at June 30, 2024, compared to $35,200 at December 31, 2023. The remaining 10,000,000 shares converted in November 2023, valued at $17,600, were recorded as an investment in StemSation stock as of June 30, 2024 at cost. Management believes the carrying values approximate fair value based on the expected recovery pursuant to the Stock Purchase Agreement covering a total of 150,000,000 shares.

During the third and fourth quarter of 2023, we purchased three convertible notes for $6,600 which included a $600 original issuance discount. During the first and second quarter of 2024, we purchased three convertible notes for $37,450 which included a $3,450 original issuance discount. They are convertible at $0.005 per share and due in one year after funding.

Amortization of convertible notes receivable recognized as other income totaled $3,150 and $3,450 for the three and six months ended June 30, 2024, respectively, compared to $1,531 and $2,431 for the three and six months ended June 30, 2023, respectively. They are recognized as other income in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023.

**12. COMMITMENTS AND CONTINGENCIES**

Operating Leases

ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. In February of 2021, we signed an updated lease with extended terms through January 1, 2023. The lease called for monthly payments of approximately $6,500 with a 4% increase each year. In October 2022, we signed another lease extension, covering the period from January 1, 2023, to December 31, 2025, with monthly payments of $7,700 and an annual 4% increase.

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2024** | **December 31,**<br>**2023** |
| **Lease cost** |  |  |
| Operating lease cost | $58518 | $97587 |
| Short-term lease cost | - | - |
| Total lease cost | $58518 | $97587 |
| **Balance sheet information** |  |  |
| Operating ROU Assets | $251951 | $251951 |
| Less accumulated amortization | (118464) | (77429) |
| Operating ROU Assets, net | $133487 | $174522 |
| Operating lease obligations, current portion | $88461 | $83703 |
| Operating lease obligations, non-current portion | 47636 | 93411 |
| Total operating lease obligations | $136097 | $177114 |
| Weighted average remaining lease term (in years) – operating leases | 1.50 | 2 |
| Weighted average discount rate-operating leases | 8% | 8% |
| Supplemental cash flow information related to leases were as follows: |  |  |
| Cash paid for amounts included in the measurement of operating lease liabilities | $37500 | $94994 |

---

Future minimum payments under these lease agreements are as follows:

---

| | |
|:---|:---|
| **December 31,** | **Total** |
| **2024(remaining 6 months)** | $47424 |
| **2025** | 97508 |
| **Total future lease payments** | $**144932** |
| **Less imputed interest** | (8835) |
| **Total** | $**136097** |

---

The Company subleases a portion of its leased facility under month-to-month arrangements. Sublease rental income is recorded as a reduction of general and administrative expenses in the condensed consolidated statements of operations, as the amounts represent recoveries of operating costs rather than revenues from the Company's primary business activities. The sublease arrangements are short-term and operate on a month-to-month basis. Total sublease rental income was approximately $30,000 and $33,000 for three and six months ended June 30, 2024, respectively, and $20,000 and $40,000 for the three and six months ended June 30, 2023, respectively.

Consulting Agreements

During July 2015, we signed an agreement with a company to provide consulting services for five years. In connection with the agreement, 500,000 shares of our restricted common stock and a one year 8% note of $50,000 were granted. The shares were valued at $0.18 per share. As the services provided were in dispute, the shares and note payable have not been issued as of June 30, 2024. As of June 30, 2024 and December 31, 2023 we have accrued $142,500 in accrued expenses on the accompanying condensed consolidated balance sheets.

During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 shares of the Company's restricted common stock were granted and the Company was to make monthly cash payments of $3,000. As of December 31, 2016, the Company recorded an equity compensation charge of $31,750, however, only 1,000,000 of the shares have been issued. As of June 30, 2024 and December 31, 2023, $19,150 has been recorded in accrued expense to account for the 1,500,000 shares of common stock that have not been issued.

During September 2022, the Company renewed its consulting agreement with an external consultant for a three-year term, providing for monthly compensation of $10,000. Consulting expenses totaled $30,000 and $60,000 for the three and six months ended June 30, 2024, respectively, compared to $30,000 and $60,000 for the corresponding periods in 2023, within selling, general and administrative expenses in the accompanying condensed consolidated statements of operations. As of June 30, 2024 and December 31, 2023, accrued consulting fees payable to this external consultant totaled $114,350 and $59,350, respectively.

**<u>Litigation</u>**

CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150

On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Company filed its Answer and Affirmative Defenses to the Complaint. The Company believes that this lawsuit is without merit. Moreover, the Company believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in the Company and fraudulently inducing the Company to enter into the subject amended promissory note. Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL, however, the mediation was unsuccessful. Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. On May 19, 2025, the Company entered into a settlement agreement with the counterparty, under which the total obligation was resolved for $125,000. The settlement terms include an initial payment of $35,000 made on May 19, 2025, followed by nine monthly payments of $10,000 each. The agreement also provides that, in the event of a payment default not cured within five business days of written notice, the counterparty may seek entry of a consent judgment against the Company in the amount of $400,000, reduced by any amounts already paid under the settlement. At June 30, 2024 and December 31, 2023, we owed a principal balance of $91,156, and accrued interest of $79,157 and $73,733, respectively (See Note 6). The total liability recorded prior to the settlement on May 19, 2025 was $178,526, consisting of $91,156 in principal and $87,370 in accrued interest. The settlement of $125,000 will result in a gain on settlement of $53,526, which will be recognized upon full satisfaction of the payment terms (see Note 14).

Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus

On September 28, 2018, the United States Securities and Exchange Commission (the "SEC") filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants' defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws.

The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company's issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company's stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief.

On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC's First Amended Complaint. On June 30, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC's request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC's Motion for Partial Summary Judgment wherein the Plaintiffs' Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants' Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik "Rik" Deitsch, and Sean McManus) Response Brief to the SEC's Motion was due May 3, 2021, and the Plaintiffs' Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants' filed a Memorandum of Law in Opposition to Plaintiff's Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021.

In July 2024, a final judgment was issued, ordering the defendant to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty. As of June 30, 2024 and December 31, 2023, the Company had accrued a total legal settlement amount of $680,235 (See Note 9).

**13. RELATED PARTY TRANSACTIONS**

The Company acts as a product formulator and contract manufacturer for Avini Health. The Company's former chief executive officer is an owner of Avini Health and is its chief scientific officer.

Commencing in May 2022, the Company sublets a portion of its space to Avini Health under a one-year sublease for a monthly rent of $5,000, with the first three months rent-free. The lease was terminated on August 31, 2023.

During 2023, the Company sold certain equipment to Avini, a related party, in connection with Avini assuming responsibility for the manufacturing of its own products. The equipment had a carrying amount of approximately $43,900 at the time of sale. The Company received proceeds of approximately $83,600, resulting in a gain of approximately $39,700, which was recognized in the fourth quarter of 2023.

During September 2023, the sales and manufacturing structure between the Company and Avini was revised. Avini assumed responsibility for manufacturing its own products, and the Company transferred to Avini certain raw materials and packaging supplies related to amounts previously advanced by Avini. In connection with this transition, the Company relocated its operations to a Boca Raton facility leased by Avini. Under this arrangement, the Company uses the facility rent-free, shares space and resources with Avini, and Avini pays all lease and office-related expenses. While sales to Avini are expected to decline beginning in 2024 as Avini manufactures its own products, the Company benefits from reduced operating costs and continued access to manufacturing capabilities for its own Nutra Pharma–branded products.

During the first quarter of 2024, the Company reclassified a portion of previously issued convertible debts for a total of $253,000 to due to officers upon the appointment of Michael Flax as the Chief Executive Officer of the Company.

During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid the principal balance in full as of December 31, 2016. During 2021 and 2022, the Company repaid $65,000 of accrued interest, including $10,000 settled through the issuance of 12,500,000 shares of common stock in 2021 in a related-party transaction. At June 30, 2024 and December 31, 2023, we owed this director accrued interest of $178,971 and $168,724. The interest expense for the three months ended June 30, 2024 and 2023 was $5,199 and $4,618, respectively, and for the six months ended June 30, 2024 and 2023 was $10,247 and $9,054, respectively.

As of June 30, 2024 and December 31, 2023, we had the following related party balances:

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2024** | **December 31,**<br>**2023** |
| Deferred revenue to a related party | $227762 | $233331 |
| Due to officers | 1108375 | 659433 |
| Accrued payroll due to officers | 1504790 | 1373693 |
| Accrued interest to a related party | 178971 | 168724 |

---

For the three months ended June 30, 2024 and 2023, we had the following related party transactions:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2024** | **June 30, 2023** |
| Net sales to a related party | $36759 | $112489 |
| Bad debt expense (recovery)- related party |  |  |
| Interest expense to a related party | 5199 | 4618 |

---

For the six months ended June 30, 2024 and 2023, we had the following related party transactions:

---

| | | |
|:---|:---|:---|
|  | **June 30, 2024** | **June 30, 2023** |
| Net sales to a related party | $71708 | $212991 |
| Bad debt expense (recovery)- related party |  | 105465 |
| Interest expense to a related party | 10247 | 9054 |

---

These transactions were not conducted at arm's length and therefore may not reflect the terms that would have been agreed to with an unrelated third party.

**14. SUBSEQUENT EVENTS**

Convertible Promissory Notes

During the fourth quarter of 2024, we issued convertible promissory notes to the unrelated third parties for a total of $63,250 with original issuance discount of $8,250. The Noteholders have the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005 per share. The notes are due one year from the execution and funding of the notes. The notes are in default and in negotiation of settlement.

In January 2025, we issued a convertible promissory note to an unrelated third party for $345,639 with original issuance discount of $45,083. The noteholder has the option to convert the outstanding principal into shares of Common Stock at a conversion price of $0.0005 per share. In connection with the issuance of the notes, we paid 10% of the proceeds to a third party, which has been recorded as a debt discount. Both the original issue discount and the issuance-related costs are being amortized over the term of the note. The notes are due one year from the execution and funding of the notes.

Between February and June 2025, we issued two convertible promissory notes to an unrelated third party for a total commitment of up to $855,000, to be funded in tranches. As of the filing date of this report, an aggregate of $592,500 has been funded. The notes carry an original issue discount of 15%, applied at the time of funding for each tranche. Each tranche matures one year from its respective execution and funding date. The noteholder has the option to convert the outstanding principal into shares of common stock at a conversion price of $0.0005 per share. If any tranches are missed or delayed by more than 10 business days, the fixed conversion price will be adjusted to $0.0008 per share for any missed tranche as a penalty. In connection with the issuance of the notes, we paid 10% of the proceeds to a third party, which has been recorded as a debt discount. Both the original issue discount and the issuance-related costs are being amortized over the term of each tranche.

During April 2025, we issued convertible promissory notes to unrelated third parties for a total of $40,250 with original issuance discount of $5,250. The Noteholders have the right to convert the notes into shares of Common Stock at a fixed conversion price of $0.0007 per share. The notes are due one year from the execution and funding of the notes.

Settlement of Convertible Debt

During the third quarter of 2024, the Company settled convertible promissory notes of $11,500, which had a conversion price of $0.0006. The Company completed repayment in the first quarter of 2025, with $11,500 in cash repayments.

Promissory Notes

In October 2024, the Company entered into a Purchase and Sale of Future Receipts Agreement with a third party. Pursuant to this agreement, the buyer purchased $99,400 of the Company's future receivables in exchange for total proceeds of $70,000, on a non-recourse basis. The Company authorized the buyer to debit its bank account at a specified remittance frequency until the full purchased amount of $99,400 was collected. In connection with this transaction, the Company recorded a total debt discount of $30,850 related to loan origination fees and issuance costs, which is being amortized over the term of the agreement.

In December 2024, the Company entered into a Purchase and Sale of Future Receipts Agreement with a third party. Pursuant to this agreement, the buyer purchased $68,500 of the Company's future receivables in exchange for total proceeds of $50,000, on a non-recourse basis. The Company authorized the buyer to debit its bank account at a specified remittance frequency until the full purchased amount of $68,500 was collected. In connection with this transaction, the Company recorded a total debt discount of $19,500 related to loan origination fees and issuance costs, which is being amortized over the term of the agreement.

Settlement of Convertible Notes Receivable

During May 2025, we purchased a convertible note from StemSation for $28,750, with original issuance discount of $3,750. The notes are convertible into common shares for $0.005 per common share and mature in one year from the funding of the notes. The original issuance discount is amortized over the lives of the notes.

On July 1, 2024, the Company entered into a one-year Research Services Agreement with StemSation, to provide research and development services on certain StemSation technologies. Under the agreement, the Company is entitled to receive $200,000 for services, payable upon execution and as requested. The contract was terminated effective June 30, 2025. The Company has received $100,000 under the agreement before it was terminated.

Settlement of Promissory Note Litigation

At June 30, 2024, the Company had a promissory note with a principal balance of $91,156 and accrued interest of $79,157, which was subject to litigation (See Note 6 and Note 12). On May 19, 2025, the Company entered into a settlement agreement with the counterparty, under which the total obligation was resolved for $125,000. The settlement terms include an initial payment of $35,000 made on May 19, 2025, followed by nine monthly payments of $10,000 each. The agreement also provides that, in the event of a payment default not cured within five business days of written notice, the counterparty may seek entry of a consent judgment against the Company in the amount of $400,000, reduced by any amounts already paid under the settlement. The total liability recorded prior to the settlement was $178,522, consisting of $91,156 in principal and $87,370 in accrued interest. The settlement of $125,000 will result in a gain on settlement of $53,526, which will be recognized upon full satisfaction of the payment terms. Payments totaling $60,000 were made during the period from June through November 2025.

Restatements of One Convertible Promissory Note

In February 2025, the note of $230,000 was further restated, with the principal balance of $230,000 subject to an additional 15% OID, while maintaining the same fixed conversion price of $0.0008. The note continues to be secured by a personal guarantee.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*Introduction*

Our business during the six months ended June 30, 2024 has focused upon marketing our homeopathic drugs for the treatment of pain:

● Nyloxin (Stage 2 Pain)

● Nyloxin Extra Strength (Stage 3 Pain)

● Pet Pain–Away

● Equine Pain–Away

● Luxury Feet

During the six months ended June 30, 2024 and thereafter, the following has occurred:

On March 22, 2024, we announced that we had reached a settlement in the civil lawsuit brought by the SEC.

**Nyloxin/Nyloxin Extra Strength**

We offer Nyloxin/Nyloxin Extra Strength as our over-the-counter (OTC) pain reliever that has been clinically proven to treat moderate to severe (Stage 2) chronic pain.

Nyloxin and Nyloxin Extra Strength are available as a two-ounce topical gel for treating joint pain and pain associated with arthritis and repetitive stress, and as a one ounce oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain. Both the topical gel and oral spray are packaged and sold as a one-month supply.

Nyloxin and Nyloxin Extra Strength offer several benefits as a pain reliever. With increasing concern about consumers using opioid and acetaminophen-based pain relievers, the Nyloxin products provide an alternative that does not rely on opiates or non-steroidal anti-inflammatory drugs, otherwise known as NSAIDs, for their pain-relieving effects. Nyloxin also has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API) of Nyloxin, Asian cobra venom, has been studied in more than 46 human clinical studies. The data from these studies provide clinical evidence that cobra venom provides an effective treatment for pain with few side effects and has the following benefits:

● safe and effective;

● all natural;

● long-acting;

● easy to use;

● non-narcotic;

● non-addictive; and

● analgesic and anti-inflammatory.

Potential side effects from the use of Nyloxin are rare, but may include headache, nausea, vomiting, sore throat, allergic rhinitis and coughing.

The primary difference between Nyloxin and Nyloxin Extra Strength is the dilution level of the venom. The approximate dilution levels for Nyloxin and Nyloxin Extra Strength are as follows:

Nyloxin

● Topical Gel: 30 mcg/mL

● Oral Spray: 70 mcg/mL

Nyloxin Extra Strength

● Topical Gel: 60 mcg/mL

● Oral Spray: 140 mcg/mL

In December 2011, we began marketing Nyloxin and Nyloxin Extra Strength at www.nyloxin.com. Both Nyloxin and Nyloxin Extra Strength are packaged in a roll-on container, squeeze bottle and as an oral spray. Additionally, Nyloxin topical gel is available in an 8 ounce pump bottle.

We are currently marketing Nyloxin and Nyloxin Extra Strength as treatments for moderate to severe chronic pain. Nyloxin is available as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress. Nyloxin Extra Strength is available as an oral spray and gel application for treating the same physical indications but is aimed at treating the most severe (Stage 3) pain that inhibits one's ability to function fully.

The Nyloxin products are available for sale on the www.Nyloxin.com website, the Nyloxin Amazon storefront at www.Amazon.com/nyloxin and on the Walmart Marketplace. Nyloxin is also sold in physician offices, clinics and small-chain pharmacies.

**Nyloxin Military Strength**

In December 2012, we announced the availability of Nyloxin Military Strength for sale to the United States Military and Veteran's Administration. Over the past few years, the U.S. Department of Defense has been reporting an increase in the use and abuse of prescription medications, particularly opiates. In 2009, close to 3.8 million prescriptions for pain relievers were written in the military. This staggering number was more than a 400% increase from the number of prescriptions written in the military in 2001. But prescription drugs are not the only issue. The most common and seemingly harmless way to treat pain is with non–steroidal, anti–inflammatory drugs (NSAIDS). But there are risks. Overuse can cause nausea, vomiting, diarrhea, heartburn, ulcers and internal bleeding. In severe cases chest pain, heart failure, kidney dysfunction and life–threatening allergic reactions can occur. It is reported that approximately 7,600 people in America die from NSAID use and some 78,000 are hospitalized. Ibuprofen, also an NSAID has been of particular concern in the military. The terms "Ranger Candy" and "Military Candy" refer to the service men and women who are said to use 800mg doses of Ibuprofen to control their pain. But when taking anti–inflammatory Ibuprofen in high doses for chronic pain, there is potential for critical health risks; abuse can lead to serious stomach problems, internal bleeding and even kidney failure. There are significantly greater health risks when abuse of this drug is combined with alcohol intake. Our goal is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military. The Nyloxin Military Strength represents the strongest version of Nyloxin available and is approximately twice as strong as Nyloxin Extra Strength. We are working with outside consultants to register Nyloxin Military Strength and the other Nyloxin products for sale to the US government and the various arms of the military as well as the Veteran's Administration. In February of 2018, Nyloxin was added to the Federal Supply Schedule but was subsequently removed the following week without an adequate explanation. We have continued to work with our consultants to understand why our products were improperly removed the Federal Supply Schedule and when we may be able to get re-listed on the Federal Supply Schedule for eventual sales to governmental agencies or to the US Military.

**International Sales**

We are pursuing international drug registrations in Canada, Mexico, India, Australia, New Zealand, Central and South America and Europe. Since European rules for homeopathic drugs are different than the rules in the US, we cannot estimate when this process will be completed. On March 25, 2013 we announced the publication of our patent and trademark for Nyloxin in India. We are actively seeking new distribution partners in India.

On May 14, 2015 we announced that we had engaged the Nature's Clinic to begin the process of regulatory approval of our Company's Over–the–Counter pain drug, Nyloxin for marketing and distribution in Canada. The Nature's Clinic has already begun setting up their Chatham, Ontario warehouse. Due to lack of funding and then the subsequent COVID crisis, we have waited to complete the approval process to begin distributing Nyloxin and expect to re-engage in the process in 2026.

Additionally, we plan to complete several human clinical studies aimed at comparing the ability of Nyloxin Extra Strength to replace prescription pain relievers. We have provided protocols to several hospitals and will provide details and timelines when those protocols have been accepted. We cannot provide any timeline for these studies until adequate financing is available.

To date, our marketing efforts have been limited due to lack of funding. As sales increase, we plan to begin marketing more aggressively to increase the sales and awareness of our products.

**Pet Pain–Away**

During June of 2013, we announced the launch of our new homeopathic formula for the treatment of chronic pain in companion animals, Pet Pain–Away. Pet Pain–Away is a homeopathic, non–narcotic, non–addictive, over–the–counter pain reliever, primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs and cats. The initial product run was completed in December of 2014 and launched through Lumaxa Distributors on December 19, 2014.

In May of 2016, we signed a license agreement to begin the process of creating an infomercial (Direct Response) campaign for Pet Pain–Away. In November of 2016, we announced the license agreement with DEG Productions for the marketing and distribution of Pet Pain–Away globally. DEG created their own website (www.getpetpainaway.com) and began airing commercials in December of 2016.

In February of 2020, we took back the marketing of Pet Pain-Away and are currently selling the product on Amazon.com and through www.petpainaway.com

**Luxury Feet**

In June of 2017, we announced the creation of *Luxury Feet*; an over–the–counter pain reliever and anti–inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos. We announced the official marketing launch of Luxury Feet in March of 2021. The product is currently available through www.luxuryfeet.com and on Amazon.

**Equine Pain-Away (Formerly Equine Nyloxin)**

In October of 2013, we announced that we were in the process of launching the newest addition to our line of homeopathic treatments for chronic pain, *Equine Nyloxin*. We had been working with trainers and veterinarians in the equine industry and have already identified distributors for the product. The *Equine Nyloxin* represents the Company's first topical solution for the animal market. Equine Nyloxin was rebranded as Equine Pain-Away™ and officially rolled into the market in October of 2019. Equine Pain-Away is being marketed through several retailers and online at www.EquinePainAway.com and on Amazon.

**Drug Discovery and Pipeline**

Nutra Pharma is developing proprietary therapeutic protein products for the biologics market. The Company has two leading drug candidates: RPI–MN and RPI–78M.

**RPI–MN**

RPI–MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and Human Immunodeficiency Virus (HIV). It is being developed first for the treatment of HIV.

**RPI–78M**

RPI–78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological and autoimmune disorders that may be served by RPI–78M include Myasthenia Gravis (MG), Rheumatoid Arthritis (RA) and Amyotrophic Lateral Sclerosis (ALS).

RPI–78M and RPI–MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to Nutra Pharma, the drugs are created through a process of chemical modification.

In September, 2015 RPI–78M was granted Orphan Status by the FDA for the treatment of pediatric Multiple Sclerosis. This allows for much shorter timelines to drug approval, waiver of FDA fees (around $2.5M), rolling review and fast–track approval. Orphan status also allows for potential grant money and other funding opportunities through the clinical process.

**RPI–MN and RPI–78M possess several desirable properties as drugs:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● They display no serious adverse side effects following years of investigations in humans and animals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● RPI–78M may be administered orally –– a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● They are easy to administer.

We are currently working with consultants to develop trial protocols for a Phase I/II trial for the use of RPI–78M in the treatment of Pediatric Multiple Sclerosis. Our goal is to initiate these trials in 2026.

**Critical Accounting Policies and Estimates**

Our condensed consolidated unaudited financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") applied on a consistent basis. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Our critical accounting policies and estimates are described in "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates" in our Annual Report on Form 10-K filed with the SEC on November 24, 2025. We evaluated the applicability of ASU 2016-03, *Intangibles – Goodwill and Other (Topic 350): Simplifying the Transition to the Equity Method of Accounting*, which became effective for us in 2023, and determined that it did not impact our financial statements. Accordingly, there were no material changes to our accounting policies during the six months ended June 30, 2024.

We regularly evaluate the accounting policies and estimates that we use to prepare our condensed consolidated financial statements. In general, management's estimates are based on historical experience, information from third party professionals, and various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management under different and/or future circumstances.

**Results of Operations – Comparison of Three-Month Periods Ended June 30, 2024 and 2023**

Net sales to unrelated customers were $51,710 for the three months ended June 30, 2024, compared to $52,398 for the same period in 2023—a slight decrease of $688, or approximately 1.31%. The slight decline reflects normal fluctuations in customer order volumes and the timing of orders during the current quarter.

Net sales to a related party, Avini Health (Avini), were $36,759 for the three months ended June 30, 2024, compared to $112,489 for the same period in 2023—a decrease of $75,730, or approximately 67.32%. The decline in sales to Avini, as Avini has begun manufacturing its own products.

Cost of sales for the three–month period ended June 30, 2024 is $18,624 compared to $80,252 for the three–month period June 30, 2023. Our cost of sales includes the direct costs associated with manufacturing, shipping and handling costs. Our gross profit margin for the three–month period ended June 30, 2024 is $54,845 or 61.99% compared to $84,635 or 51.33% for the three–month period ended June 30, 2023. The gross margin has improved, primarily reflecting lower manufacturing costs associated with sales to a related party, despite recording of a $15,000 reserve for undelivered venom and slow-moving inventory during the current quarter, which did not occur in the prior-year period.

Selling, general and administrative expenses increased $7,399, or 2.77%, from $266,939 for the quarter ended June 30, 2023 to $274,338 for the quarter ended June 30, 2024, primarily due to an increase in payroll related to compensation for newly appointed officers and higher legal fees associated with a legal matter which was subsequently settled in 2025. These increases were partially offset by reductions in certain payroll and office-related costs under the new arrangement with Avini.

Other income was $3,150 and $31,894 for the three months ended June 30, 2024 and 2023, respectively. The amounts primarily relate to the amortization of debt discounts on convertible notes receivable, which totaled $3,150 and $3,450 for the three months ended June 30, 2024 and 2023, respectively. The significantly higher amount recognized in the second quarter of 2023 was primarily attributable to services rendered in exchange for a convertible note receivable.

Interest expense, including related party interest expense, decreased $3,476 or 3.84%, from $90,522 for the quarter ended June 30, 2023 to $87,046 for the quarter ended June 30, 2024. This decrease was primarily due to the decrease in amortization of loan discounts in the quarter ended June 30, 2024 compared to the quarter ended June 30, 2023.

We carry certain of our debentures and common stock warrants at fair value. Due to the fact that the number of shares of common stock issuable could exceed the Company's authorized share limit, the equity environment is tainted, and all additional convertible debt, options and warrants are included in the value of the derivative liabilities. For the three months ended June 30, 2024 and 2023, the liability related to these hybrid instruments fluctuated, resulting in a loss of $56,250 and $38,314, respectively. Interest expense on these debentures is included in the fair value loss in the accompanying unaudited condensed consolidated statements of operations.

Loss on settlement of debts increased $7,500 from no loss for the three months ended June 30, 2023 to a loss of $7,500 for the three months ended June 30, 2024, reflecting one debt settlement executed during the current quarter.

As a result of the foregoing, our net loss increased by $87,893 or 31.48%, from net loss of $279,246 for the quarter ended June 30, 2023 to a net loss of $367,139 for the quarter ended June 30, 2024.

**Results of Operations – Comparison of Six-Month Periods Ended June 30, 2024 and 2023**

Net sales to unrelated customers were $89,422 for the six months ended June 30, 2024, compared to $106,920 for the same period in 2023—a slight decrease of $17,478, or approximately 16.35%. The decline reflects normal fluctuations in customer order volumes and the timing of orders during the six months period.

Net sales to a related party, Avini Health (Avini), were $71,708 for the six months ended June 30, 2024, compared to $212,991 for the same period in 2023—a decrease of $141,283, or approximately 66.33%. There is a decline in sales to Avini, as Avini has begun manufacturing its own products.

Cost of sales for the six–month period ended June 30, 2024 is $41,108 compared to $132,177 for the six–month period June 30, 2023. Our cost of sales includes the direct costs associated with manufacturing, shipping and handling costs. Our gross profit margin for the six–month period ended June 30, 2024 is $90,042 or 55.87% compared to $187,734 or 58.68% for the six–month period ended June 30, 2023. The decline in gross margin was primarily attributable to the recording of a $30,000 reserve for undelivered venom and slow-moving inventory during the six month periods, which did not occur in the prior-year period. Excluding this $30,000 reserve, gross margin would have improved, primarily reflecting lower manufacturing costs associated with sales to a related party.

Selling, general and administrative expenses decreased $58,415, or 8.81%, from $663,259 for the six months ended June 30, 2023 to $604,844 for the six months ended June 30, 2024, primarily due to reductions in certain payroll and office-related costs under the new arrangement with Avini, as well as an overall decline in legal fees following the settlement of the Company's major lawsuit in late March 2024. These decreases were partially offset by increased compensation related to newly appointed officers. In addition, we had a bad debt expense of $0 and $105,465 from the receivables from companies controlled by the Company's former CEO for the six months ended June 30, 2024 and 2023, respectively.

Other income was $3,450 and $32,794 for the six months ended June 30, 2024 and 2023, respectively. The amounts primarily relate to the amortization of debt discounts on convertible notes receivable, which totaled $3,450 and $4,350 for the six months ended June 30, 2024 and 2023, respectively. The significantly higher amount recognized in the six months ended June 30, 2023 was primarily attributable to services rendered in exchange for a convertible note receivable.

Interest expense, including related party interest expense, decreased $59,424 or 25.5%, from $233,075 for the six months ended June 30, 2023 to $173,651 for the six months ended June 30, 2024. This decrease was primarily due to the decrease in amortization of loan discounts in the six months ended June 30, 2024 compared to the six months ended June 30, 2023.

We carry certain of our debentures and common stock warrants at fair value. Due to the fact that the number of shares of common stock issuable could exceed the Company's authorized share limit, the equity environment is tainted, and all additional convertible debt, options and warrants are included in the value of the derivative liabilities. For the six months ended June 30, 2024 and 2023, the liability related to these hybrid instruments fluctuated, resulting in a loss of $122,990 and $90,185, respectively. Interest expense on these debentures is included in the fair value loss in the accompanying unaudited condensed consolidated statements of operations.

Loss on settlement of debts and accrued expenses decreased by $14,270, from a loss of $350 for the six months ended June 30, 2023 to a net gain of $13,920 for the six months ended June 30, 2024. This change was primarily attributable to a one-time gain resulting from a debt settlement executed through the issuance of common stock during the first quarter of 2024, driven by fluctuations in the Company's stock price.

As a result of the foregoing, our net loss decreased by $77,733 or 8.92%, from net loss of $871,806 for the six months ended June 30, 2023 to a net loss of $794,073 for the six months ended June 30, 2024.

**Liquidity and Capital Resources**

We have incurred significant losses from operations and working capital and stockholders' deficits raise substantial doubt about our ability to continue as a going concern. Further, as stated in Note 1 to our condensed consolidated unaudited financial statements for the period ended June 30, 2024, we have an accumulated deficit of $75,739,547 at June 30, 2024. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $14,640,377 and a stockholders' deficit of $14,558,881 at June 30, 2024.

Our ability to continue as a going concern is contingent upon our ability to secure additional financing, increase ownership equity, and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern. In addition, our common stock is presently on the OTC Market Group's Expert Market, which means that the Company's common stock is not eligible for proprietary broker-deal quotes.

Current operations are primarily being funded through a combination of product sales, promissory notes and convertible notes. During the six months ended June 30, 2024, we raised $174,000 through the issuance of convertible notes and $69,840 through the issuance of a promissory notes.

We expect to utilize the proceeds from these funds and additional capital to manufacture Nyloxin and Pet Pain–Away and reduce our debt level. We estimate that we will require approximately $600,000 to fund our existing operations over the next twelve months. These costs include: (i) compensation for six (6) full-time employees; (ii) compensation for various consultants who we deem critical to our business; (iii) general office expenses including rent and utilities; (iv) product liability insurance; and (v) outside legal and accounting services. These costs reflected in (i) – (v) do not include research and development costs or other costs associated with clinical studies.

Our ability to meet our future operating expenses is highly dependent on the amount of such future revenues. To the extent that future revenues from the sales of Nyloxin and Pet Pain-Away are insufficient to cover our operating expenses we may need to raise additional equity capital, which could result in substantial dilution to existing shareholders. There can be no assurance that we will be able to raise sufficient equity capital to fund our working capital requirements on terms acceptable to us, or at all. We may also seek additional loans from our officers and directors; however, there can be no assurance that we will be successful in securing such additional loans.

The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

**Uncertainties and Trends**

Our operations and possible revenues are dependent now and in the future upon the following factors:

● Whether we successfully develop and commercialize products from our research and development activities.

● If we fail to compete effectively in the intensely competitive biotechnology area, our operations and market position will be negatively impacted.

● If we fail to successfully execute our planned partnering and out-licensing of products or technologies, our future performance will be adversely affected.

● The recent economic downturn and related credit and financial market crisis may adversely affect our ability to obtain financing, conduct our operations and realize opportunities to successfully bring our technologies to market.

● Biotechnology industry related litigation is substantial and may continue to rise, leading to greater costs and unpredictable litigation.

● The decline in sales to Avini, as Avini has begun manufacturing its own products. This shift is expected to reduce our revenues going forward and may require us to develop new customer relationships or product lines to offset the reduction.

● If we fail to comply with extensive legal/regulatory requirements affecting the healthcare industry, we will face increased costs, and possibly penalties and business losses.

**Off–Balance Sheet Arrangements**

We have not entered into any transaction, agreement or other contractual arrangement with an entity unconsolidated with us under whom we have:

● An obligation under a guarantee contract.

● A retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to such entity for such assets.

● Any obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument.

● Any obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by us and material to us where such entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with us.

We do not have any off-balance sheet arrangements or commitments that have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material, other than those which may be disclosed in this Management's Discussion and Analysis of Financial Condition and the audited Consolidated Financial Statements and related notes.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Not applicable

**Item 4. Controls and Procedures**

*Disclosure Controls and Procedures*

As of June 30, 2024, we carried out an evaluation under the supervision and the participation of our Chief Executive Officer/Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of June 30, 2024, as defined in Rule 13a–15 under the Securities Exchange Act of 1934 ("Exchange Act"). Based on that evaluation, our management, including our Chief Executive Officer/Chief Financial Officer, concluded that, because of the material weaknesses in internal control over financial reporting discussed in Section 9A of our annual report on Form 10–K, our disclosure controls and procedures were not effective, at a reasonable assurance level, as of June 30, 2024. In light of this, we performed additional post–closing procedures and analyses in order to prepare the Condensed Consolidated Unaudited Financial Statements included in this report. As a result of these procedures, we believe our Condensed Consolidated Unaudited Financial Statements included in this report present fairly, in all material respects, our financial condition, results of operations and cash flows for the periods presented. A control system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the company have been detected.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer, who also acted as our Principal Financial Officer as appropriate, to allow timely decisions regarding required disclosure.

*Changes in Internal Control over Financial Reporting*

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a–15 or 15d–15 under the Exchange Act that occurred during the quarter ended June 30, 2024 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150

On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Company filed its Answer and Affirmative Defenses to the Complaint. The Company believes that this lawsuit is without merit. Moreover, the Company believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in the Company and fraudulently inducing the Company to enter into the subject amended promissory note. Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL, however, the mediation was unsuccessful. Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. On May 19, 2025, the Company entered into a settlement agreement with the counterparty, under which the total obligation was resolved for $125,000. The settlement terms include an initial payment of $35,000 made on May 19, 2025, followed by nine monthly payments of $10,000 each. The agreement also provides that, in the event of a payment default not cured within five business days of written notice, the counterparty may seek entry of a consent judgment against the Company in the amount of $400,000, reduced by any amounts already paid under the settlement. The total liability recorded prior to the settlement on May 19, 2025 was $178,526, consisting of $91,156 in principal and $87,370 in accrued interest. The settlement of $125,000 will result in a gain on settlement of $53,526, which will be recognized upon full satisfaction of the payment terms.

Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus

On September 28, 2018, the United States Securities and Exchange Commission (the "SEC") filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants' defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws.

The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company's issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company's stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief.

On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC's First Amended Complaint. On June 30, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC's request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC's Motion for Partial Summary Judgment wherein the Plaintiffs' Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants' Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik "Rik" Deitsch, and Sean McManus) Response Brief to the SEC's Motion was due May 3, 2021, and the Plaintiffs' Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants' filed a Memorandum of Law in Opposition to Plaintiff's Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021.

In July 2024, a final judgment was issued, ordering the defendant to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty. As of June 30, 2024 and December 31, 2023, the Company had accrued a total legal settlement amount of $680,235.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

There were no unregistered sales of equity securities.

**Item 3. Defaults Upon Senior Securities**

*Debt owed to a Director*

During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid the principal balance in full as of December 31, 2016. During 2021 and 2022, the Company repaid $65,000 of accrued interest, including $10,000 settled through the issuance of 12,500,000 shares of common stock in 2021 in a related-party transaction. In April 2022, we repaid $10,000 of accrued interest. At June 30, 2024 and December 31, 2023, we owed this director accrued interest of $178,971 and $168,724, respectively.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Title** |
| 31.1 | [Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes–Oxley Act of 2002.](ex31-1.htm) |
| 32.1 | [Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes–Oxley Act of 2002.](ex32-1.htm) |
| 101.INS | Inline XBRL Instance Document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**<u>SIGNATURES</u>**

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | NUTRA PHARMA CORP. |
|  | Registrant |
| Dated: December 23, 2025 | */s/ Michael Flax, DDS* |
|  | Michael Flax, DDS |
|  | Chief Executive Officer/Chief Financial Officer |

---

## Exhibit 31.1

**Exhibit 31.1**

**NUTRA PHARMA CORP.**

**OFFICER'S CERTIFICATE PURSUANT TO SECTION 302**

I, Michael Flax, the Chief Executive Officer and Chief Financial Officer of Nutra Pharma Corp., certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I
 have reviewed this quarterly report on Form 10-Q of Nutra Pharma Corp.;

2. Based
 on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact
 necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
 to the period covered by this quarterly report;

3. Based
 on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all
 material respects the financial condition, results of operations and cash flows of the Small Business Issuer as of, and for, the
 periods presented in this quarterly report;

4. The
 Small Business Issuer's other certifying officers and I are responsible for establishing and maintaining disclosure controls
 and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
 in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Small Business Issuer and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known
 to us by others within those entities, particularly during the period in which this report is being prepared;

(b) [Omitted
 pursuant to SEC Release No. 33-8238];

(c) Evaluated
 the effectiveness of the Small Business Issuer's disclosure controls and procedures and presented in this report our conclusions
 about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
 evaluation; and

(d) Disclosed
 in this report any change in the Small Business Issuer's internal control over financial reporting that occurred during the
 small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of
 an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal
 control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The
 Small Business Issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
 over financial reporting, to the small business issuer's auditors of the small business issuer's board of directors (or
 persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial
 information; and

(b) Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's
 internal control over financial reporting.

---

| |
|:---|
| Dated: December 23, 2025 |
| */s/ Michael Flax, DDS* |
| Michael Flax, DDS |
| Chief Executive Officer/Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Nutra Pharma Corp., (the "Company") on Form 10-Q for the quarterly period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Michael Flax, the Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The
 Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The
 information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
 of the Company.

---

| |
|:---|
| Dated: December 23, 2025 |
| */s/ Michael Flax, DDS* |
| Michael Flax, DDS |
| Chief Executive Officer and Chief Financial Officer |

---